Placebo
DrugPatients undergoing different cardiac surgical procedures will receive a continuous intravenous infusion of Normal Saline 0.9% with a starting dose of 0.0025 ml/kg/min.
NCT Number: NCT04312971
The primary objective is to test the efficacy and safety of the accuracy of continuous intravenous infusion of norepinephrine during cardiopulmonary bypass (CPB) on the prevention of hyperlactatemia after cardiac surgery.
"Efficacy" would be tested with measurement of the postoperative changes in lactic acid level over time from the baseline value before induction of general anesthesia.
"safety" would be tested with observing the post-cardiotomy need for inotropic and vasopressor support, the incidence of postoperative acute kidney injury (AKI), changes in cardiac troponin level (CnTnI), and signs of ischemic splanchnic injury.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Not applicable
Dammam University, Khobar, Eastern Province, Saudi Arabia
Rationale
1.1. Vasoplegia and cardiac surgery:
Vasoplegia Syndrome (VS), prevailing in about 20% of cardiac surgical procedures (1), is defined as low mean arterial pressure (MAP) with normal or high cardiac indices and which is resistant to treatment with the commonly used vasopressors. (2,3) Vasoplegia might occur either during or after the cardiopulmonary bypass periods or during the postoperative period during the intensive care unit (ICU) stay. (3) Many factors have been found to be related to the increased Vasoplegia during the cardiopulmonary bypass period such as left ventricular ejection fraction more than 40%, male patients, elderly patients, higher body mass index, long cardiopulmonary bypass time, hypotension upon the start of cardiopulmonary bypass, perioperative use of angiotensin-converting enzyme inhibitors (ACE) and presence of infective endocarditis. (4,5)
1.2. Effects of Cardiopulmonary bypass (CPB) on Post cardiotomy Vasoplegia.
Cardiopulmonary bypass itself may intensify the effects of vasoplegia due to hemodilution which decreases the blood viscosity, so, reducing the overall peripheral vascular resistance. Moreover, the interaction of blood with the tubing of the cardiopulmonary bypass machine results in the release of inflammatory mediators which play an important role in reducing the peripheral resistance and aggravating the hypotension. Although compensatory and auto-regulatory mechanisms play an important role in maintaining adequate tissue perfusion, hypotension during the cardiopulmonary bypass period may result in poor outcomes as postoperative stroke (4) especially if the mean arterial pressure is below 65 mmHg. (6)
1.3. Hyperlactatemia after cardiac surgery
Lactate was used as a marker for adequate tissue perfusion since the mid-1800s. Although the literature has illustrated the undesirable effects of high lactate levels, however, the cause, the prevention as well as treatment measures of hyperlactatemia remain obscure. Additionally, lactic acidosis or hyperlactatemia might occur in cases of refractory vasoplegia. A rise in lactate levels is common during cardiac surgery and is well known for its deleterious and its association with poor patients' outcomes. (7)
Owing to its detrimental effects, measures to reduce the effects and treat vasoplegia were used. Firstly, excluding any equipment or mechanical failure such as the arterial line monitor, adjusting the bypass flows for higher cardiac index (CI>2.2), confirming the proper cannula position and ruling out any aortic dissection.
Secondly, adjusting some physiological parameters is of great value as checking hematocrit level for excessive hemodilution, adjusting the anesthetics with severe vasodilatory properties, excluding the possibility of a drug reaction or anaphylaxis and temperature management during hypothermic bypass.
Thirdly, the use of conventional vasopressor agents as phenylephrine, norepinephrine, and vasopressin. Finally, the use of some off-label agents as vitamin C, hydroxocobalamin, angiotensin 2, methylene blue and prostaglandin inhibitors. (8)
1.4. Why this clinical trial?
The use of norepinephrine during CPB has its own potential benefits. It is not clear if the use of continuous norepinephrine infusion during CPB would be effective and safe in lessening the postoperative hyperlactatemia and development of vasoplegia after cardiac surgery.
The here proposed randomized controlled clinical trial will test the use of continuous norepinephrine infusion during CPB with respect to the efficacy and safety to reduce the postoperative rise in blood lactate level.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Patients undergoing different cardiac surgical procedures will receive a continuous intravenous infusion of Normal Saline 0.9% with a starting dose of 0.0025 ml/kg/min.
Patients undergoing different cardiac surgical procedures will receive a continuous intravenous infusion of norepinephrine (40 ug/ml) with a starting dose of 0.0025 ml/kg/min.
Infusion rate will be increased as needed in order to maintain a MAP ≥65 mmHg during cardiopulmonary bypass period as per the discretion of the anesthesiologist using 0.00125 ml/kg/min increments
Infusion rate will be decreased as needed in order to maintain a MAP ≥65 mmHg during cardiopulmonary bypass period as per the discretion of the anesthesiologist using 0.00125 ml/kg/min decrements
Time frame: For 24 hours after surgery from the start of surgery
perioperative changes in lactic acid level measured from arterial or venous blood
Time frame: For 24 hours after surgery from the start of surgery
invasive arterial blood pressure measurement
Time frame: For 24 hours after surgery from the start of surgery
measured as l/min/m2
Time frame: For 24 hours after surgery from the start of surgery
measured as dynes.sec.m2/cm5
Time frame: For 24 hours after surgery from the start of surgery
measured as ml/min/m2
Time frame: For the time of surgery
Use of rescue doses of phenylephrine
Time frame: For the time of surgery
Use of rescue doses of norepinephrine
Time frame: For the time of surgery
Use of rescue doses of ephedrine
Time frame: For the time of surgery
Use of rescue doses of nitroglycerine
Time frame: For the time of surgery
Use of rescue doses of labetalol
Time frame: For the time of surgery
Use of rescue doses of esmolol
Time frame: For the time of surgery
Use of rescue doses of atropine
Time frame: For the time of surgery
Use of rescue doses of glycopyrrolate
Time frame: For the time of surgery
Decrease of peripheral oxygen saturation less than 92%
Time frame: For the time of surgery
Increase in end tidal carbon dioxide more than 45 mm Hg
Time frame: For the time of surgery
Number of drops in systolic arterial pressure < 90 mmHg for 3 minutes or longer for any reasons
Time frame: For the time of surgery
Number of drops in heart rate lower than 40 beats.min-1 or 10% of baseline value for more than three minutes for any reasons.
Time frame: For the time of surgery
Remarkable ischemic changes included those patients with ≥ 1- mv ST-segment depression or ≥ 2-mv ST-segment elevation lasting more than 1 minute
Time frame: For the time of surgery
Need for pacemaker insertion following termination of cardiopulmonary bypass.
Time frame: For the time of surgery
Need for direct current shock following termination of cardiopulmonary bypass..
Time frame: For the time of surgery
Need for epinephrine following termination of cardiopulmonary bypass.
Time frame: For the time of surgery
Need for norepinephrine following termination of cardiopulmonary bypass.
Time frame: For the time of surgery
Need for dobutamine following termination of cardiopulmonary bypass.
Time frame: For the time of surgery
Need for milrinone following termination of cardiopulmonary bypass.
Time frame: For the time of surgery
Need for intra-aortic balloon counter pulsation pump following termination of cardiopulmonary bypass.
Time frame: For the time of surgery
The amount of transfused units of blood and blood products
Time frame: For the time of surgery
The amount of infused crystalloids and colloids
Time frame: For 30 days after surgery
Length of ICU stay
Time frame: For 30 days after surgery
Length of hospital stay
Time frame: For 30 days after surgery
Alive or dead on postoperative day 30
Time frame: For 90 days after surgery
Alive or dead on postoperative day 90
Time frame: For 30 days after surgery
Postoperative need for reintubation during the first 30 days following surgery
Time frame: For 30 days after surgery
Postoperative bleeding during the first 30 days following surgery
Time frame: For 30 days after surgery
Postoperative cariogenic shock for the first 30 days following surgery
Time frame: For 30 days after surgery
Postoperative acute kidney injury for the first 30 days following surgery
Time frame: For 30 days after surgery
Postoperative mesenteric or splanchnic ischemia for the first 30 days following surgery
Time frame: For 30 days after surgery
Postoperative acute coronary syndrome for the first 30 days following surgery
Time frame: For 30 days after surgery
Postoperative wound infection for the first 30 days following surgery
Time frame: For 30 days after surgery
Postoperative pneumonia for the first 30 days following surgery
Time frame: For 30 days after surgery
Postoperative mediastinitis for the first 30 days following surgery
Time frame: For 30 days after surgery
Postoperative decrease in peripheral oxygen saturation less than 90 for the first 30 days following surgery
Time frame: For 30 days after surgery
Postoperative stroke for the first 30 days following surgery
Time frame: For 30 days after surgery
Postoperatively during hospital stay
Time frame: For 30 days after surgery
Postoperatively during hospital stay
Imam Abdulrahman Bin Faisal University
Other
Effects of Norepinephrine Infusion During Cardiopulmonary Bypass on Perioperative Changes in Lactic Acid Level: A Randomized Controlled Study
Acronym: Norcal
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03772990
Cardiac Surgery, Cardiopulmonary Bypass
Manama, Bahrain
View Trial DetailsNCT03624595
Cardiac Surgery, Cardiopulmonary Bypass
Beijing, Beijing Municipality, China
View Trial DetailsNCT02675647
Cardiac Surgery, Cardiopulmonary Bypass
Strasbourg, France
View Trial DetailsNCT04871308
Cardiac Surgery, Cardiopulmonary Bypass
Seoul, South Korea
View Trial Details